The modern fitness landscape has seen a significant rise in Exertional Rhabdomyolysis (ER), a potentially life-threatening condition traditionally associated with extreme endurance or military combat. As high-intensity functional training and aggressive indoor cycling become mainstream, recreational athletes are increasingly exposed to metabolic crises previously rare in the commercial gym sector. This review examines the pathophysiology of ER, beginning with the ATP depletion-calcium dysregulation cascade that leads to myocyte necrosis and the systemic release of intracellular contents. Central to the clinical concern is the "Nephrotoxic Triad" - a synergistic mechanism involving renal vasoconstriction, oxidative stress via the Fenton Reaction, and physical tubular obstruction by myoglobin casts, which precipitates Acute Kidney Injury (AKI). The article identifies a "perfect storm" of risk factors, including eccentric loading, heat strain, and the pervasive, unsupervised use of NSAIDs, which disable the kidney’s autoregulatory mechanisms. Diagnosis remains challenging, as the classic triad of symptoms is present in less than 10% of cases; thus, the review highlights the importance of serum Creatine Kinase (CK) and the emerging utility of Cystatin C as a muscle-mass-independent biomarker for renal function. Management focus is placed on aggressive, early fluid resuscitation using balanced crystalloids to induce forced diuresis. Finally, the review proposes a four-phase return-to-play protocol, emphasizing a risk-stratified approach to transition athletes safely from recovery to sport-specific activity while mitigating the long-term risks of chronic kidney disease and recurrence.
Background: Stimulant medications are the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), but their increasing use and potential long-term physiological costs warrant reevaluation. Objective: This narrative review examines the effectiveness of stimulants compared to non-stimulant medications and non-pharmacological interventions, considering both short-term symptom relief and long-term developmental outcomes. Methods: Data from the Multimodal Treatment Study (MTA) 14-month and 16-year follow-ups were synthesized with contemporary meta-analyses and cohort studies. Key metrics included Standardized Mean Differences (SMD) for efficacy and Incidence Rate Ratios (IRR) for safety. Results: Stimulants show high acute efficacy for core symptoms (SMD 0.81–1.10), but long-term MTA data reveal no significant symptom reduction by early adulthood. Extended use carries costs, including adult height suppression (2.55 cm in consistent users) and increased cardiovascular risk (IRR 1.41) within six months. Behavioral therapies (BT) have lower blinded efficacy for core symptoms (SMD 0.12) but better outcomes in functional domains such as organizational skills (SMD 0.85). Combined treatment maintains symptom control at lower stimulant doses (31.2 mg vs. 37.7 mg/day). Non-stimulants like Atomoxetine offer moderate benefit (Hedges’ g ≈ −0.48) with different safety profiles, including higher somnolence but less height suppression. Conclusion: Effective ADHD management requires moving from symptom-focused pharmacological monotherapy to a multimodal, lifespan-oriented approach. Behavioral interventions provide essential support for functional outcomes. Combined strategies remain the clinical gold standard, optimizing efficacy while potentially reducing long-term physiological risks of stimulants.
Background: Lateral elbow tendinopathy (LET) is a prevalent musculoskeletal disorder characterized by pain and functional impairment at the common extensor origin. This narrative review explores the critical paradigm shift from the historical inflammatory "epicondylitis" model to a modern mechanobiological framework. Objective: To synthesize current evidence-based perspectives on the pathophysiology, diagnosis, and management of LET, emphasizing the optimization of quality of care through active loading protocols. Evidence Synthesis: Pathophysiological understanding has evolved from an inflammatory model to one of tendinosis, characterized by angiofibroblastic hyperplasia and a failed healing response. Clinical diagnosis relies on provocative maneuvers and objective measures, specifically Pain-Free Grip Strength (PFGS) and the Patient-Rated Tennis Elbow Evaluation (PRTEE), to ensure diagnostic quality and monitor therapeutic efficacy. A critical appraisal of passive interventions, such as corticosteroid injections and NSAIDs, highlights their limitations and potential for long-term clinical failure. In contrast, mechanotransduction-driven active protocols—including isometric loading for acute analgesia and Heavy Slow Resistance (HSR) training for structural remodeling—represent the modern gold standard. Furthermore, the integration of a biopsychosocial framework and the enhancement of patient health literacy are essential for addressing nociplastic pain and ensuring sustainable functional reintegration. Conclusions: Effective management of LET requires a structured, criterion-based transition to active management, prioritizing therapeutic loading over passive symptom masking to maximize long-term musculoskeletal health and minimize recurrence.
Cytochrome P450 (CYP) enzymes are membrane-bound hemoproteins responsible for the metabolism of numerous important compounds. In humans, they are responsible for nearly 80% of oxidative reactions and approximately 50% of total drug elimination, mainly within the CYP1–CYP3 families. The CYP3A4 isoenzyme, involved in the metabolism of around 50% of drugs used in clinical practice, along with the highly polymorphic CYP2C9 and CYP2C8 genes, are key members of the cytochrome P450 subfamily. Their genetic variability, which may result in abolished, quantitatively or qualitatively altered or enhanced metabolism, varies among populations and geographical regions. This review presents the frequency and diversity of CYP2C8, CYP2C9 and CYP3A4 alleles across European countries.